Indegene Acquires Medical Marketing Economics (MME)

Founded in 1998 by five first generation entrepreneurs, Indegene has emerged as a leading digital transformation partner to the global life sciences industry. Indegene is a technology-led healthcare solutions provider. It combines deep industry expertise with fit-for-purpose technology in an agile and scalable operating model.

Indegene recently announced its new brand expression, aligned with its purpose to enable healthcare organizations be future ready. In a short span of time, healthcare organizations developed life-saving products, while pivoting to a digital-first operating model. Indegene played a key role in this transformation.

Investment firms The Carlyle Group and Brighton Park Capital recently acquired a minority stake in Indegene for $200 million. The transaction consists of a secondary sale from existing shareholders and a primary investment. The funding values the firm at $700 million.

Indegene has acquired market-access advisory Medical Marketing Economics (MME) for $10 million, as it seeks to bolster its biopharma pricing and reimbursement capabilities. MME and its team of 40 people, spread between Montclair, NJ, and Oxford, MS, will continue to operate as a standalone business.

Indegene plans to expand its operations by hiring specialized talent as well as through specific acquisitions that complement its business. The company plans to hire up to 2,500 people this fiscal year across offices, out of which about 2,000 will be based in India, 200 in North America, 100 in Japan and China, and the remaining in Europe. It has a total headcount of about 4,000 employees globally. 


Takeaway: Indegene is expanding its commercialization capabilities with the acquisition